Krystal Biotech Inc
NASDAQ:KRYS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Krystal Biotech Inc
NASDAQ:KRYS
|
US |
|
A
|
Amazon.com Inc
SGO:AMZN
|
US |
|
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
US |
|
Ducommun Inc
NYSE:DCO
|
US |
|
GLG Corp Ltd
ASX:GLE
|
SG |
|
Investec PLC
LSE:INVP
|
UK |
|
Assystem SA
PAR:ASY
|
FR |
|
N
|
Nippon Telegraph and Telephone Corp
XBER:NTT
|
JP |
|
F
|
Fresenius SE & Co KGaA
OTC:FSNUY
|
DE |
|
A
|
Advanced Energy Industries Inc
SWB:AVX
|
US |
|
Scandic Hotels Group AB
STO:SHOT
|
SE |
|
China Securities Co Ltd
SSE:601066
|
CN |
|
Container Corporation of India Ltd
NSE:CONCOR
|
IN |
|
B
|
Britania PCL
SET:BRI
|
TH |
|
Marathon Oil Corp
NYSE:MRO
|
US |
|
Hello Group Inc
NASDAQ:MOMO
|
CN |
|
S
|
SPAR Group Ltd
JSE:SPP
|
ZA |
Wall St Price Targets
KRYS Price Targets Summary
Krystal Biotech Inc
According to Wall Street analysts, the average 1-year price target for KRYS is 315.49 USD with a low forecast of 217.15 USD and a high forecast of 418.95 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is KRYS's stock price target?
Price Target
315.49
USD
According to Wall Street analysts, the average 1-year price target for KRYS is 315.49 USD with a low forecast of 217.15 USD and a high forecast of 418.95 USD.
What is the Revenue forecast for Krystal Biotech Inc?
Projected CAGR
22%
The compound annual growth rate for Revenue over the next 8 years is 22%.
What is the Operating Income forecast for Krystal Biotech Inc?
Projected CAGR
31%
The compound annual growth rate for Operating Income over the next 8 years is 31%.
What is the Net Income forecast for Krystal Biotech Inc?
Projected CAGR
19%
The compound annual growth rate for Net Income over the next 8 years is 19%.
